Semaglutide for Treatment of People With Methamphetamine Use Disorder: the SHIFT Study
ConditionMethamphetamine Use Disorder
Trial statusNot yet recruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18+
SponsorKirby Institute
About this trial
Methamphetamine use disorder is a major public health concern in Australia and globally. GLP-1 medications such as semaglutide (e.g. Ozempic) are approved for diabetes and medication, and may potentially affect craving for other substances apart from food. We do not know if this will help people who use methamphetamine ('ice') to reduce their use. This study will treat people who use methamphetamine with weekly injections of semaglutide. It will provide data on if this is a potentially safe and practical treatment for this group of people.
Eligibility criteria
Qualifiers
Has provided voluntary, written informed consent;
Aged 18 years or older;
Diagnosed with moderate to severe methamphetamine use disorder (DSM-5 criteria);
Self-reported methamphetamine use on at least 14 of past 28 days and a positive oral fluid drug screen for amphetamine/methamphetamine;
Disqualifiers
Uncontrolled medical or psychiatric conditions that may interfere with participation;
Body mass index less than 22 kg/m2;
Confirmed diagnosis of diabetes mellitus (either known history of diabetes; concomitant treatment with insulin, metformin, sulfonylureas, thiazolidinediones, SGLT2 inhibitor, DPP4 inhibitor; or HbA1c >6.5 at screening);
Currently taking a GLP-1 receptor agonist;
Trial design
Treatments tested in this trial
- 12 weeks of weekly subcutaneous semaglutide injection
Treatment groups
40 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov